About: Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin
Creator	Acet, Ahmet Parlakpinar, Hakan Polat, Seyhan
source	Medline; PMC
abstract	Coronavirus disease 2019 (COVID‐19) is a life‐threatening infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). COVID‐19 pandemic causing morbidities and even deaths worldwide revealed that there is urgent need to find pharmacological agents or vaccines. Although there are a lot of agents under investigation, there is no approved agent for the prevention or treatment of the COVID‐19 yet. Treatment of patients remains mainly supportive as well as compassionate use of the agents under investigation. It is well established that excessive inflammatory and immune response as well as oxidative injury play a critical role in the pathogenesis of COVID‐19. In this review, we aimed to update knowledge about pathogenesis, clinical features and pharmacological treatment of COVID‐19 and review the potential beneficial effects of ancient antioxidant, anti‐inflammatory and immunomodulatory molecule melatonin for prevention and treatment of COVID‐19.
has issue date	2020-07-13(xsd:dateTime)
bibo:doi	10.1111/fcp.12589
bibo:pmid	32657483
has license	no-cc
sha1sum (hex)	c8987f12fa246bdb2347ec01dc210c35074476fa
schema:url	https://doi.org/10.1111/fcp.12589
resource representing a document's title	Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin
has PubMed Central identifier	PMC7405383
has PubMed identifier	32657483
schema:publication	Fundam Clin Pharmacol
resource representing a document's body	covid:c8987f12fa246bdb2347ec01dc210c35074476fa#body_text
is schema:about of	named entity 'melatonin' named entity 'oxygen therapy' named entity 'cytokine storm' named entity 'lung' named entity 'adrenergic receptor' named entity 'mercaptopurine' named entity 'IL-6' named entity 'Soluble' named entity 'lung edema' named entity 'reoxygenation' named entity 'melatonin' named entity 'MERS-CoV' named entity 'gas exchange' named entity 'metallopeptidase' named entity 'N-acetyltransferase' named entity 'anaphylaxis' named entity 'neutropenia' named entity 'ACE2' named entity 'intestine' named entity 'Melatonin' named entity 'double-blind, placebo-controlled' named entity 'open label' named entity 'neuroblastoma cells' named entity 'Bcl-2' named entity 'TNF-α' named entity '12 weeks' named entity 'SARS-CoV' named entity 'IL-6 receptor' named entity 'ventilator-induced lung injury' named entity 'melatonin' named entity 'pathogenesis' named entity 'ACE2' named entity 'abnormal liver function tests' named entity 'testicular' named entity 'ACE2' named entity 'Tocilizumab' named entity 'cytoprotective' named entity 'MAS' named entity 'randomized controlled trial' named entity 'activated B cells' named entity 'adenylyl cyclase' named entity 'RdRP' named entity 'EBOV' named entity 'oxidative stress' named entity 'melatonin' named entity 'antioxidant' named entity 'ACE2' named entity 'experimental models' named entity 'nucleotide oligomerization domain' named entity 'kidney' named entity 'placental' named entity 'renal damage' named entity 'protein' named entity 'IL-6' named entity 'prophylaxis' named entity 'viral disease' named entity 'COVID' named entity 'melatonin' named entity 'melatonin' named entity 'liver' named entity 'Melatonin' named entity 'protein' named entity 'mice' named entity 'hypoxemia' named entity 'melatonin' named entity 'extracellular' named entity 'ACE2' named entity 'melatonin' named entity 'Ebola' named entity '09:00' named entity 'half life' named entity 'HO-1' named entity 'minks' named entity 'antigen presentation' named entity 'RSV infection' named entity 'Melatonin' named entity 'melatonin' named entity 'anti-inflammatory effect' named entity 'remdesivir'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software